Marex Group’s DexCom DXCM Stock Holding History

Marex Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,000	Closed	-$465K	–	1083
2025 Q4	$465K	Hold	7,000	–	–	﹤0.01%	587
2025 Q3	$471K	Buy	+7,000	New	+$554K	﹤0.01%	512

Other funds holding DXCM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Marex Group's DXCM Position: Q4 2025 in Review

Marex Group sold out of DexCom (DXCM) in Q4 2025, closing a stake of 3,343 shares — an estimated $216K sold.

Marex Group first reported a position in DXCM in Q4 2024 and held it in 2 quarters. The position peaked at $347K in Q4 2024. 920 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

Marex Group reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
Marex Group sold 3,343 DexCom shares in Q4 2025, an estimated $216K.
Marex Group first reported a position in DexCom in Q4 2024 and held it in 2 quarters.
Marex Group's DexCom position peaked at $347K in Q4 2024.
920 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on Marex Group's 13F filing for Q4 2025, filed 12 Feb 2026.